Adient (ADNT) Cash & Equivalents (2015 - 2026)

Adient (ADNT) has 12 years of Cash & Equivalents data on file, last reported at $831.0 million in Q1 2026.

• Quarterly Cash & Equivalents rose 10.21% year-over-year to $831.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $831.0 million (up 10.21% YoY) and the FY2025 annual result came in at $958.0 million, up 1.38% from the prior year.
• Cash & Equivalents eased to $831.0 million in Q1 2026, from $855.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.1 billion in Q1 2022 to a low of $754.0 million in Q1 2025.
• A 5-year average of $914.7 million and a median of $901.0 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents slumped 56.68% — and 2023, when it advanced 17.21%.
• Tracing ADNT's Cash & Equivalents over 5 years: stood at $901.0 million in 2022, then increased by 9.88% to $990.0 million in 2023, then fell by 13.13% to $860.0 million in 2024, then decreased by 0.58% to $855.0 million in 2025, then retreated by 2.81% to $831.0 million in 2026.
• The last three Cash & Equivalents figures came in at $831.0 million (Q1 2026), $855.0 million (Q4 2025), and $958.0 million (Q3 2025), per Business Quant data.